Summit Global Investments Neurocrine Biosciences Inc Transaction History
Summit Global Investments
- $1.34 Billion
- Q1 2024
A detailed history of Summit Global Investments transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Summit Global Investments holds 49,477 shares of NBIX stock, worth $6.81 Million. This represents 0.51% of its overall portfolio holdings.
Number of Shares
49,477
Previous 40,733
21.47%
Holding current value
$6.81 Million
Previous $5.37 Million
27.15%
% of portfolio
0.51%
Previous 0.35%
Shares
7 transactions
Others Institutions Holding NBIX
# of Institutions
628Shares Held
94.4MCall Options Held
505KPut Options Held
343K-
Black Rock Inc. New York, NY13.8MShares$1.89 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.93MShares$1.37 Billion0.03% of portfolio
-
State Street Corp Boston, MA3.99MShares$549 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.3MShares$316 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.25MShares$310 Million0.49% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.2B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...